1. Home
  2. NEO vs COLL Comparison

NEO vs COLL Comparison

Compare NEO & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEO
  • COLL
  • Stock Information
  • Founded
  • NEO 2001
  • COLL 2002
  • Country
  • NEO United States
  • COLL United States
  • Employees
  • NEO N/A
  • COLL N/A
  • Industry
  • NEO Precision Instruments
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • NEO Health Care
  • COLL Health Care
  • Exchange
  • NEO Nasdaq
  • COLL Nasdaq
  • Market Cap
  • NEO 1.0B
  • COLL 958.8M
  • IPO Year
  • NEO 1999
  • COLL 2015
  • Fundamental
  • Price
  • NEO $8.62
  • COLL $36.16
  • Analyst Decision
  • NEO Buy
  • COLL Strong Buy
  • Analyst Count
  • NEO 10
  • COLL 4
  • Target Price
  • NEO $12.56
  • COLL $44.25
  • AVG Volume (30 Days)
  • NEO 2.9M
  • COLL 444.4K
  • Earning Date
  • NEO 11-04-2025
  • COLL 11-06-2025
  • Dividend Yield
  • NEO N/A
  • COLL N/A
  • EPS Growth
  • NEO N/A
  • COLL N/A
  • EPS
  • NEO N/A
  • COLL 1.06
  • Revenue
  • NEO $689,189,000.00
  • COLL $707,007,000.00
  • Revenue This Year
  • NEO $10.40
  • COLL $22.23
  • Revenue Next Year
  • NEO $10.11
  • COLL $2.78
  • P/E Ratio
  • NEO N/A
  • COLL $34.01
  • Revenue Growth
  • NEO 9.70
  • COLL 22.61
  • 52 Week Low
  • NEO $4.72
  • COLL $23.23
  • 52 Week High
  • NEO $19.12
  • COLL $42.29
  • Technical
  • Relative Strength Index (RSI)
  • NEO 65.05
  • COLL 46.84
  • Support Level
  • NEO $7.60
  • COLL $34.71
  • Resistance Level
  • NEO $8.42
  • COLL $36.57
  • Average True Range (ATR)
  • NEO 0.51
  • COLL 1.27
  • MACD
  • NEO 0.02
  • COLL -0.58
  • Stochastic Oscillator
  • NEO 74.12
  • COLL 28.60

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: